JP2013184887A5 - - Google Patents

Download PDF

Info

Publication number
JP2013184887A5
JP2013184887A5 JP2012048422A JP2012048422A JP2013184887A5 JP 2013184887 A5 JP2013184887 A5 JP 2013184887A5 JP 2012048422 A JP2012048422 A JP 2012048422A JP 2012048422 A JP2012048422 A JP 2012048422A JP 2013184887 A5 JP2013184887 A5 JP 2013184887A5
Authority
JP
Japan
Prior art keywords
sap155
inhibitor
firδexon2
fir
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012048422A
Other languages
Japanese (ja)
Other versions
JP6057408B2 (en
JP2013184887A (en
Filing date
Publication date
Application filed filed Critical
Priority to JP2012048422A priority Critical patent/JP6057408B2/en
Priority claimed from JP2012048422A external-priority patent/JP6057408B2/en
Publication of JP2013184887A publication Critical patent/JP2013184887A/en
Publication of JP2013184887A5 publication Critical patent/JP2013184887A5/ja
Application granted granted Critical
Publication of JP6057408B2 publication Critical patent/JP6057408B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (9)

SAP155阻害剤、FIR-SAP155阻害剤、およびFIRΔexon2-SAP155阻害剤からなる群から選択される１種または２種以上を有効成分として含有する癌の予防剤および／または治療剤。   A prophylactic and / or therapeutic agent for cancer comprising, as an active ingredient, one or more selected from the group consisting of SAP155 inhibitors, FIR-SAP155 inhibitors, and FIRΔexon2-SAP155 inhibitors. SAP155阻害剤を有効成分として含有し、当該SAP155阻害剤が二重鎖RNA部分に下記のヌクレオチド配列を含むsiRNAである、癌の予防剤および／または治療剤：
A prophylactic and / or therapeutic agent for cancer, comprising an SAP155 inhibitor as an active ingredient, wherein the SAP155 inhibitor is a siRNA comprising the following nucleotide sequence in the double-stranded RNA portion:
FIR-SAP155阻害剤を有効成分として含有し、当該FIR-SAP155阻害剤がFIR-SAP155結合阻害剤である、癌の予防剤および／または治療剤。   A preventive and / or therapeutic agent for cancer, comprising a FIR-SAP155 inhibitor as an active ingredient, wherein the FIR-SAP155 inhibitor is a FIR-SAP155 binding inhibitor. 前記FIR-SAP155結合阻害剤が、下記の化学式からなる群から選択される１種または２種以上の化合物である、請求項３に記載の癌の予防剤および／または治療剤：
The prophylactic and / or therapeutic agent for cancer according to claim 3, wherein the FIR-SAP155 binding inhibitor is one or more compounds selected from the group consisting of the following chemical formulas:
前記FIR-SAP155結合阻害剤が、下記の化学式からなる群から選択される１種または２種以上の化合物である、請求項３に記載の癌の予防剤および／または治療剤：The prophylactic and / or therapeutic agent for cancer according to claim 3, wherein the FIR-SAP155 binding inhibitor is one or more compounds selected from the group consisting of the following chemical formulas:
FIRΔexon2-SAP155阻害剤を有効成分として含有し、当該FIRΔexon2-SAP155阻害剤がFIRΔexon2-SAP155結合阻害剤である、癌の予防剤および／または治療剤。   A prophylactic and / or therapeutic agent for cancer comprising a FIRΔexon2-SAP155 inhibitor as an active ingredient, wherein the FIRΔexon2-SAP155 inhibitor is a FIRΔexon2-SAP155 binding inhibitor. 前記FIRΔexon2-SAP155結合阻害剤が、下記の化学式からなる群から選択される１種または２種以上の化合物である、請求項６に記載の癌の予防剤および／または治療剤：
The prophylactic and / or therapeutic agent for cancer according to claim 6 , wherein the FIRΔexon2-SAP155 binding inhibitor is one or more compounds selected from the group consisting of the following chemical formulas:
前記FIRΔexon2-SAP155結合阻害剤が、下記の化学式からなる群から選択される１種または２種以上の化合物である、請求項６に記載の癌の予防剤および／または治療剤：
The prophylactic and / or therapeutic agent for cancer according to claim 6 , wherein the FIRΔexon2-SAP155 binding inhibitor is one or more compounds selected from the group consisting of the following chemical formulas:
試験物質を、SAP155、FIR、およびFIRΔexon2の少なくともいずれかと接触させる工程と、
前記試験物質がSAP155、FIR、およびFIRΔexon2の少なくともいずれかの機能、あるいは、SAP155とFIRとの結合、またはSAP155とFIRΔexon2との結合の少なくともいずれかを阻害するか否かを判定する工程と、
を含む、癌の予防剤および／または治療剤の候補物質の同定方法。 Contacting the test substance with at least one of SAP155, FIR, and FIRΔexon2,
Determining whether the test substance inhibits at least one of the functions of SAP155, FIR, and FIRΔexon2, or the binding of SAP155 and FIR, or the binding of SAP155 and FIRΔexon2, and
A method for identifying a candidate substance for a prophylactic and / or therapeutic agent for cancer, comprising:
JP2012048422A 2012-03-05 2012-03-05 Cancer preventive and / or therapeutic agent Active JP6057408B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2012048422A JP6057408B2 (en) 2012-03-05 2012-03-05 Cancer preventive and / or therapeutic agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2012048422A JP6057408B2 (en) 2012-03-05 2012-03-05 Cancer preventive and / or therapeutic agent

Publications (3)

Publication Number Publication Date
JP2013184887A JP2013184887A (en) 2013-09-19
JP2013184887A5 true JP2013184887A5 (en) 2015-04-23
JP6057408B2 JP6057408B2 (en) 2017-01-11

Family

ID=49386650

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012048422A Active JP6057408B2 (en) 2012-03-05 2012-03-05 Cancer preventive and / or therapeutic agent

Country Status (1)

Country Link
JP (1) JP6057408B2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6304594B2 (en) * 2014-05-29 2018-04-04 国立大学法人千葉大学 Aromatic ring-containing compound and preventive and / or therapeutic agent for cancer
ES2887201T3 (en) 2015-09-01 2021-12-22 Eisai R&D Man Co Ltd Splice variants associated with neomorphic mutants of SF3B1

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2510087A2 (en) * 2009-12-11 2012-10-17 The Brigham and Women's Hospital, Inc. Pathogen restriction factors
TW201204393A (en) * 2010-04-16 2012-02-01 Daiichi Sankyo Co Ltd Diagnostic agent and therapeutic agent of cancer

Similar Documents

Publication Publication Date Title
JP2008245635A5 (en)
JP2011168588A5 (en)
JP2017522908A5 (en)
MX367666B (en) Compositions and methods for quantifying a nucleic acid sequence in a sample.
IN2014DN04226A (en)
UA118649C2 (en) Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr)
CL2011002524A1 (en) Compounds of substituted 1,3-diazol-phenyl- (ethynyl, ethenyl or cyclopropyl) -phenyl-1,3-diazole substituted, ns5a inhibitors; pharmaceutical composition that includes them and their use in the treatment of hepatitis c.
WO2012095639A3 (en) Methods, compositions, and kits for determing the presence/absence of a varian nucleic acid sequence
WO2008151631A3 (en) Use of short oligonucleotides for reagent redundancy experiments in rna functional analysis
EA201070421A1 (en) MICRORIPONIC ACID
EP3995580A3 (en) Compounds and methods for modulation of dystrophia myotonica-protein kinase (dmpk) expression
WO2012149339A3 (en) Quantification of a minority nucleic acid species
WO2012006589A3 (en) Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
WO2016065349A3 (en) Short non-coding protein regulatory rnas (sprrnas) and methods of use
EA201490993A1 (en) MODIFIED MEANS OF RNA
WO2008113111A8 (en) Assay for gene expression
MX349787B (en) Oral dosage forms including an antiplatelet agent and an acid inhibitor.
EP2224017A4 (en) Method for amplifying target nucleic acid sequence and probe used for the same
EA201200323A1 (en) COMPOUNDS AND COMPOSITIONS AS PROTEINKINASE INHIBITORS
ATE461699T1 (en) IMPROVED BIOLOGICAL EFFECTS OF COMPOSITIONS CONTAINING ROSMARIC ACID
CL2008001517A1 (en) Device for determining the risk of melanoma progression comprising oligonucleotides of one or more melanoma prognostic markers (mpms) chosen from a selection group; procedure for determining the prognosis of melanoma in a patient; Procedure for determining the suitability of a melanoma patient for a drug trial.
EA201290822A1 (en) TRIAZOLONES AS FATTY ACIDS SYNTHASE INHIBITORS
EP2314680A4 (en) Method for amplification of target nucleic acid sequence, method for detection of mutation by using the method, and reagents for use in the methods
BR112013002738A2 (en) methods and compounds for cancer diagnosis and treatment
BR112014029274A2 (en) isolated antibody, pharmaceutical composition, use of the antibody, method for treating rabies infection, kit for treating rabies infection, kit for detecting rabies virus, isolated nucleic acid, and host cell.